Sirprakuline aneemia
Anemia Management
A phase 1b/2 study of the efficacy and safety of combination hydroxyurea and dose-escalated erythropoietin for treatment of anemia in sickle cell disease (ACHiEvE-SCD). (avab uue akna)
Allikas: Blood 2024;144(Suppl 1):178-9.
Indekseeritud: DOI
DOI: 10.1182/blood-2024-205261
Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. (avab uue akna)
Allikas: Eur J Haematol 1996;56(5):326-8.
Indekseeritud: PubMed 8641410
On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (avab uue akna)
Allikas: Acta Haematol 1995;94(3):128-34.
Indekseeritud: PubMed 7502628
Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (avab uue akna)
Allikas: Haematologica 2006;91(8):1076-83.
Indekseeritud: PubMed 16885048
https://www.ncbi.nlm.nih.gov/pubmed/16885048 (avab uue akna)
Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (avab uue akna)
Allikas: J Obstet Gynaecol 2007;27(1):82-3.
Indekseeritud: PubMed 17365469
DOI: 10.1080/01443610601062739
https://www.ncbi.nlm.nih.gov/pubmed/17365469 (avab uue akna)
The use of barbiturate coma as salvage therapy in a postoperative Jehovah's Witness patient with life-threatening anemia. (avab uue akna)
Allikas: Am Surg 2009;75(12):1175-8.
Indekseeritud: PubMed 19999907
https://www.ncbi.nlm.nih.gov/pubmed/19999907 (avab uue akna)